Athersys, Inc. said Monday it has received approval from the U.S. Food and Drug Administration to start a Phase 2/3 trial to assess the safety and efficacy of its MultiStem therapy in patients with moderate to severe acute respiratory distress syndrome or ARDS induced by COVID-19. According to the World Health Organization, ARDS is the leading cause of death among COVID-19 infected patients.
from RTT - Biotech https://ift.tt/3a7bWrE
via IFTTT
No comments:
Post a Comment